Trichomonas vaginalis Virus: Current Insights and Emerging Perspectives
- PMID: 40733518
- PMCID: PMC12298157
- DOI: 10.3390/v17070898
Trichomonas vaginalis Virus: Current Insights and Emerging Perspectives
Abstract
Trichomonas vaginalis, a prevalent sexually transmitted protozoan parasite, is associated with adverse birth outcomes, increased risk of HIV and other sexually transmitted infections, infertility, and cervical cancer. Despite its widespread impact, trichomoniasis remains underdiagnosed and underreported globally. Trichomonas vaginalis virus (TVV), a double-stranded RNA (dsRNA) virus infecting T. vaginalis, could impact T. vaginalis pathogenicity. We provide an overview of TVV, including its genomic structure, transmission, impact on protein expression, role in 5-nitroimidazole drug susceptibility, and clinical significance. TVV is a ~5 kbp dsRNA virus enclosed within a viral capsid closely associated with the Golgi complex and plasma membrane of infected parasites. Hypothetical mechanisms of TVV transmission have been proposed. TVV affects protein expression in T. vaginalis, including cysteine proteases and surface antigens, thus impacting its virulence and ability to evade the immune system. Additionally, TVV may influence the sensitivity of T. vaginalis to treatment; clinical isolates of T. vaginalis not harboring TVV are more likely to be resistant to metronidazole. Clinically, TVV-positive T. vaginalis infections have been associated with a range in severity of genital signs and symptoms. Further research into interactions between T. vaginalis and TVV is essential in improving diagnosis, treatment, and the development of targeted interventions.
Keywords: TVV; Totiviridae; Trichomonas vaginalis virus; Trichomonasvirus; double-stranded RNA virus.
Conflict of interest statement
Christina A. Muzny, MD, MSPH, has received research grant support to her institution from NIH/NIAID, Gilead, Visby Medical, BioNTech, and Abbott. She also reports honorarium and/or consulting fees from Cepheid, BioNTech, bioMérieux, Elsevier, UpToDate, and Abbott.
Figures

Similar articles
-
Trichomonas vaginalis virus: a review of the literature.Int J STD AIDS. 2019 Apr;30(5):496-504. doi: 10.1177/0956462418809767. Epub 2019 Jan 9. Int J STD AIDS. 2019. PMID: 30626281
-
Atomic Structure of the Trichomonas vaginalis Double-Stranded RNA Virus 2.mBio. 2021 Mar 30;12(2):e02924-20. doi: 10.1128/mBio.02924-20. mBio. 2021. PMID: 33785622 Free PMC article.
-
Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates.Microbiol Spectr. 2025 Jul;13(7):e0271724. doi: 10.1128/spectrum.02717-24. Epub 2025 May 22. Microbiol Spectr. 2025. PMID: 40401974 Free PMC article.
-
Molecular characterization of double-stranded RNA virus in Trichomonas vaginalis Egyptian isolates and its association with pathogenicity.Parasitol Res. 2016 Oct;115(10):4027-36. doi: 10.1007/s00436-016-5174-3. Epub 2016 Jun 17. Parasitol Res. 2016. PMID: 27316695
-
Systematic review and meta-analysis of the global prevalence and infection risk factors of Trichomonas vaginalis.Parasite. 2025;32:56. doi: 10.1051/parasite/2025051. Epub 2025 Aug 27. Parasite. 2025. PMID: 40864904 Free PMC article.
References
-
- Rowley J., Vander Hoorn S., Korenromp E., Low N., Unemo M., Abu-Raddad L.J., Chico R.M., Smolak A., Newman L., Gottlieb S., et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bull. World Health Organ. 2019;97:548–562. doi: 10.2471/BLT.18.228486. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources